CSIMarket

Medidata Solutions Inc   (MDSO)
Other Ticker:  
 
    Sector  Technology    Industry Software & Programming
   Industry Software & Programming
   Sector  Technology
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 62
 Employees 1,680
 Revenues (TTM) (Millions $) 685
 Net Income (TTM) (Millions $) 44
 Cash Flow (TTM) (Millions $) 34
 Capital Exp. (TTM) (Millions $) 54

Medidata Solutions Inc

Medidata is a global life sciences technology provider, dedicated to improving the way clinical research is designed, conducted, and analyzed. Our cloud-based platform of solutions and data analytics enables efficiency and quality throughout clinical development programs by accelerating processes, enhancing decision-making, minimizing operational risk, saving resources, and enabling transformational trial strategies.

Customers can utilize our entire platform or purchase individual solutions or products. We offer our technology on an enterprise or multi-study basis. Customers can also use our solutions on a single-study basis for a limited number of trials or to evaluate them prior to committing to a multi-study arrangement. Subscription and professional services represent approximately 85% and 15% of our business, respectively. Our business model provides us with a recurring revenue stream that we believe delivers greater revenue visibility than perpetual software licensing models.

The Medidata Clinical Cloud
Medidata's unified platform, pioneering analytics, and clinical technology expertise power the development of new therapies for nearly 1,000 pharmaceutical companies, biotech and medical device firms, academic medical centers and contract research organizations ("CROs") around the world. The Medidata Clinical Cloud connects patients, physicians, and life sciences professionals. Companies on the Medidata platform are individually and collaboratively reinventing the way research is done to create smarter, more precise treatments.

It Starts With Data Capture and Management
The Medidata Clinical Cloud already powers the clinical trials of the future, including numerous master protocols, platform studies, and even trials that use synthetic control patients. It seamlessly captures and integrates the abundance of data streams and biomarker measurements that today's targeted therapies demand, not only from clinics and labs, but also from sensors, apps, images, genomics, and real world evidence ("RWE"). By capturing and integrating such a wide array of study data, the Medidata Clinical Cloud also automates many of the most challenging data management workflows across randomization, supply, coding, and safety. It is now possible for patients to electronically consent, be randomized, and receive their first supply all on their first visit. Medical terms can be coded automatically with natural language processing and machine learning.

Rich Data Capture Leads to Pioneering Analytics
The Medidata Clinical Cloud is underpinned by the Medidata Enterprise Data Store ("MEDS"). This cross-sponsor data store of de-identified study data contains the scientific and operational data from over 13,000 studies, half a million site and sponsor interactions, and 3.8 million patients, which are aggregated and standardized in a variety of ways to supply data sets. These data sets power analytics and benchmarking visualizations that enable smarter decision making, resulting in reduced patient burden and increased patient enrollment and retention. In addition, predictive analytics and machine learning throughout the Medidata platform drive intelligent processes such as risk-based monitoring ("RBM") and automated genomic clustering. MEDS also addresses the growing challenge of patient scarcity; Medidata's synthetic control arm and synthetic control data solutions enable organizations to leverage historical controls from statistically similar indications and studies to reduce the need to recruit new control patients.


Pioneering Analytics Accelerate Trial Planning and Management
Clinical complexity is increasing the burden of managing and operationalizing clinical studies. Minimizing patient burden in protocol design while optimizing site selection, grants, and payments in trial planning is a critical success factor to trial execution. Medidata's study design optimization, site feasibility, site grants, and payments solutions use historical benchmarks and automation from MEDS to optimize patient burden, site selection, grants, and payments, leading to increased patient recruitment and retention rates.


Medidata also solves many of the biggest challenges in trial management. Medidata's strategic monitoring and clinical trial management system ("CTMS") solutions address regulatory requirements for RBM by combining anomaly detection with intelligent workflows to enable sponsors, CROs, and sites to confidently move away from 100% source document verification. Medidata's master data management means that the majority of the artifacts in an electronic trial master file ("eTMF") can be pre-populated from other sources.



   Company Address: 350 Hudson Street, 9th Floor New York 10014 NY
   Company Phone Number: 918-1800   Stock Exchange / Ticker: NASDAQ MDSO
   


Customers Net Income grew by MDSO's Customers Net Profit Margin grew to

31.98 %

15.97 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

Year to Date Decrease / Increase
     
APPN   -34.75%    
DBX   -16.95%    
NOW   -38.29%    
ORCL   -28.25%    
QADB        92.4% 
VEEV   -35.73%    
IBM   -9.76%    
IQV   -32.13%    
• View Complete Report
   



Innsuites Hospitality Trust

Innsuites Hospitality Trust declared very difficult period in the second quarter of 2022

In the second quarter of 2022 Innsuites Hospitality Trust eps remained unchanged of $0.01 per share compared to $0.01 a year ago and profit plummeted by -50 % from $0.02 per share from the previous quarter.

Nate s Food Co.

Sales and Earnings Unchanged at Nate S Food Co in the fourth quarter of 2022

In the fourth quarter of 2022 Nate S Food Co reached break-even of $0.00 per share compared to $0.00 a year ago and from $0.00 per share from the previous quarter.

Global Arena Holding Inc.

Break-even, Top-line Crumbles

Global Arena Holding Inc recorded operating shortfall of $-0.231176 millions, in the financial interval ending Jun 30 2022, a degradation from the operating shortfall of $-0.193016 millions, reported in second quarter of 2021

Sunwin Stevia International Inc.

Break-even by Sunwin Stevia International Inc in the most recent fiscal period statement

Sunwin Stevia International Inc recorded operating loss of $-0.075911 millions, in the most recent fiscal period, a progress from the operating shortfall of $-0.256339 millions, reported in first quarter of 2021

Defense Technologies International Corp.

Defense Technologies International Corp disclosed top-line remained unaltered in the fiscal first quarter of 2022

In the fiscal first quarter of 2022 Defense Technologies International Corp reached break-even of $0.00 per share compared to $-0.02 a year ago and from $-0.00 per share from the previous quarter.






 

Medidata Solutions Inc 's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Medidata Solutions Inc does not provide revenue guidance.

Earnings Outlook
Defense Technologies International Corp. does not provide earnings estimates.

 
Geographic Revenue Dispersion


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

RMSL's Profile

Stock Price

RMSL's Financials

Business Description

Fundamentals

Charts & Quotes

RMSL's News

Suppliers

RMSL's Competitors

Customers & Markets

Economic Indicators

RMSL's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071